CUBICIN

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, UK.

Active ingredients

The drug CUBICIN contains one active pharmaceutical ingredient (API):

1	Daptomycin UNII NWQ5N31VKK - DAPTOMYCIN
	Daptomycin is a cyclic lipopeptide natural product that is active against Gram positive bacteria only. The mechanism of action involves binding to bacterial membranes of both growing and stationary phase cells causing depolarisation and leading to a rapid inhibition of protein, DNA, and RNA synthesis.
	Read more about Daptomycin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CUBICIN Powder for concentrate for solution for injection or infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01XX09	Daptomycin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01X Other antibacterials → J01XX Other antibacterials
Discover more medicines within J01XX09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	525517100020117, 525517100020217
CA	Health Products and Food Branch	02465493
EE	Ravimiamet	1257779, 1257780, 1492938, 1492949
ES	Centro de información online de medicamentos de la AEMPS	05328001, 05328002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	061961, 061970
FR	Base de données publique des médicaments	62442395, 69811090
GB	Medicines & Healthcare Products Regulatory Agency	101402, 109616
HK	Department of Health Drug Office	57551
IL	מִשְׂרַד הַבְּרִיאוּת	7073
JP	医薬品医療機器総合機構	6119402D1021
LT	Valstybinė vaistų kontrolės tarnyba	1028352, 1028353, 1063651, 1063652
NL	Z-Index G-Standaard, PRK	90883
NZ	Medicines and Medical Devices Safety Authority	13186
PL	Rejestru Produktów Leczniczych	100165318, 100165324
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64829001, W64829002, W64830001, W64830002
SG	Health Sciences Authority	13501P
US	FDA, National Drug Code	67919-011, 67919-012
ZA	Health Products Regulatory Authority	43/20.1/0954